ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Wacker Chemie, the German specialty chemicals firm, has opened a new facility for making messenger RNA (mRNA)–based active ingredients for medicines such as vaccines and cancer drugs at its site in Halle, Germany. The facility, which cost over $100 million, has four mRNA production lines. It more than triples Wacker’s production capacity at Halle, to over 200 million vaccine doses annually. The company plans to open a biotech center in Munich later this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X